Business: Abbott India Limited

MOLECULE: Vi-Capsular Polysaccharide of S. typhi Ty2 conjugated to Tetanus Toxoid + Sodium chloride + water

FORM: Pre Filled Syringe

STRENGTH: Each 0.5 mL prefilled syringe contains purified Vi-Capsular Polysaccharide of S. typhi Ty2 conjugated to Tetanus Toxoid 25 μg, Sodium chloride 4.5 mg and water for Injections q.s. to 0.5 mL.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: Respiratory,Vaccine

Business: Abbott India Limited

MOLECULE: A/California/7/2009 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/2/2012

FORM: Injection

STRENGTH: 0.5 ml prefilled syringe

BUSINESS AREAS: Pharmaceuticals

THERAPY AREAS: Vaccine

Business: Abbott India Limited

MOLECULE: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181)+ A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) + B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type)

FORM: Pre filled Syringe

STRENGTH: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181) 7.5 mcg HA, A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) 7.5 mcg HA, B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type) 7.5 mcg HA per 0.25 mL dose. This vaccine complies with the WHO recommendation (northern hemisphere) and competent authority decision for the 2016/2017 season.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: Vaccine

Business: Abbott India Limited

MOLECULE: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181)+ A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) + B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type)

FORM: Pre Filled Syringe

STRENGTH: Influenza virus surface antigens (hemagglutinin and neuraminidase) of the following strains (propagated in fertilized hens' eggs from healthy chicken flocks) A/California/7/2009 (H1N1)pdm09-like strain (A/California/ 7/2009, X-181) 15 mcg HA, A/Hong Kong/4801/2014 (H3N2)-like strain (A/New Caledonia/71/2014, X-257A) 15 mcg HA, B/Brisbane/60/2008-like strain(B/Brisbane/60/2008, wild type) 15 mcg HA per 0.5 mL dose. This vaccine complies with the WHO recommendation (northern hemisphere) and competent authority decision for the 2016/2017 season.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: Vaccine

Business: Abbott India Limited

MOLECULE: Purified, inactivated Japanese Encephalitis Virus protein (JE strain 821564-XY) + Aluminum Hydroxide gel + Thiomersal (Preservative) + Phosphate buffered saline

FORM: Vial

STRENGTH: Each Dose of 0.5 mL contains: Purified, inactivated Japanese Encephalitis Virus protein NLT 5.0 μg (JE strain 821564-XY), Aluminum Hydroxide gel as Al+++ IP 0.25 mg, Thiomersal (Preservative) IP 0.025 mg, Phosphate buffered saline q.s. to 0.5 ml.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: Vaccine

Business: Abbott India Limited

MOLECULE: Diphtheria Toxoid + Tetanus Toxoid + B. pertussis (Whole cell inactivated) + HBsAg (rDNA) + Hib PRP-TT Conjugate + Aluminium Phosphate gel as Aluminium (Al+++) + Thiomersal

FORM: Pre Filled Syringe

STRENGTH: Pre-filled syringe of 0.5 ml. Each syringe contains Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus Influenzae type b Conjugate Vaccine (Adsorbed) I.P. Each dose of 0.5 mL contains: Diphtheria Toxoid 20 Lf to <30 Lf ( 30 IU), Tetanus Toxoid 5 Lf to 25 Lf ( 60 IU), B. pertussis (Whole cell inactivated) 4 IU, HBsAg (rDNA) 10 μg, Hib PRP-TT Conjugate 10 μg, Aluminium Phosphate gel as Aluminium (Al+++) 0.3 mg, Thiomersal IP 0.021 mg to 0.029 mg.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: GI & Hepato,Vaccine

Business: Abbott India Limited

MOLECULE: Rotavirus 116E NLT 105.0 FFU + Potassium phosphate monobasic + Potassium phosphate dibasic + Sucrose + Potassium L-glutamate monohydrate + Neomycin sulphate + Kanamycin sulphate + Dulbecco’s Modi ed Eagle’s Medium + water

FORM: Vial

STRENGTH: Each 0.5 ml contains Rotavirus 116E NLT 105.0 FFU, Potassium phosphate monobasic IP 0.258 mg, Potassium phosphate dibasic IP 0.625 mg, Sucrose IP 37.31 mg, Potassium L-glutamate monohydrate 1.0 mg, Neomycin sulphate IP 15 μg, Kanamycin sulphate IP 15 μg, Dulbecco’s Modi ed Eagle’s Medium 4.4 mg and water for Injection IP q.s, pH is in the range of 7.2 to 8.0.

BUSINESS AREAS: PHARMACEUTICALS ABBOTT INDIA LIMITED,Vaccine

THERAPY AREAS: GI & Hepato,Vaccine